Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $147.57 and traded as low as ...

In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a ...

The parties will collaborate to conduct a Phase II clinical trial to evaluate the combination of an experimental ...

BusinessWire India Accra [Ghana]Mumbai Maharashtra [India] January 9 Merck Foundation the philanthropic arm of Merck KGaA ...

BOSTON and TEL-AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Quris-AI, an artificial intelligence (AI) innovator disrupting ...

BOSTON and TEL-AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Quris-AI, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced that Merck KGaA, Darmstadt ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

DARMSTADT, Germany, Jan. 6, 2025 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck, a leading science and technology company, today launched a beta version of M-Trust™, a secure cyber-physical trust ...

Other companies with checkpoint inhibitors on the market also have HCC in its sights, including Merck KGaA/Pfizer whose Bavencio (avelumab) PD-L1 inhibitor is in phase II testing in this indication.